"Erythropoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
| Descriptor ID |
D004921
|
| MeSH Number(s) |
D12.644.276.374.410.240.150 D12.776.395.240.150 D12.776.467.374.410.240.150 D23.529.374.410.240.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Erythropoietin".
Below are MeSH descriptors whose meaning is more specific than "Erythropoietin".
This graph shows the total number of publications written about "Erythropoietin" by people in this website by year, and whether "Erythropoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 6 | 0 | 6 |
| 2008 | 4 | 4 | 8 |
| 2009 | 5 | 0 | 5 |
| 2010 | 6 | 1 | 7 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 5 | 0 | 5 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Erythropoietin" by people in Profiles.
-
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant. 2023 07 31; 38(8):1890-1897.
-
The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
-
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
-
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
-
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
-
Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO. Am J Nephrol. 2022; 53(5):361-365.
-
Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019 11; 28(6):600-606.
-
Cause of Death in Patients With Diabetic CKD Enrolled in the?Trial to Reduce Cardiovascular Events With Aranesp Therapy?(TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40.
-
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem. Semin Dial. 2013 Sep-Oct; 26(5):531-4.
-
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.